References

  1. NeuroStar Prescribing Information.
  2. Avery, et al. (2008). Transcranial Magnetic Stimulation in the Acute Treatment of Major Depressive Disorder: Clinical Response in an Open-Label Extension Trial. J Clin Psychiatry, 69 (3):441-451.
  3. Janicak PG and Dokucu ME (2015). Transcranial magnetic stimulation for the treatment of major depression. Neuropsychiatr Dis Treat, 11:1549–1560.
  4. Data on file. Neuronetics, Inc.
  5. Janicak PG, et al. (2010). Durability of Clinical Benefit with Transcranial Magnetic Stimulation (TMS) in the Treatment of Pharmacoresistant Major Depression: Assessment of Relapse During a 6-Month, Multisite, Open-Label Study. Brain Stimulation, 3(4):187-199. www.ncbi.nlm.nih.gov/pubmed/20965447
  6. Trivedi MH, et al. (2006). Evaluation of Outcomes with Citalopram for Depression Using Measurement-Based Care in STAR*D Implications for Clinical Practice. Am J Psychiatry, 163(1):28-40
  7. Rush AJ, et. al. (2006) Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: a STAR*D report. Am J Psychiatry, 163(11):1905-1917.
  8. Dunner DL, et al. (2014). A Multisite, Naturalistic, Observational Study of Transcranial Magnetic Stimulation (TMS) for Patients with Pharmacoresistant Major Depressive Disorder: Durability of Benefit Over a 1-Year Follow-Up Period. J Clin Psychiatry. 75(12):1394-1401. www.ncbi.nlm.nih.gov/pubmed/25271871
  9. O’Reardon JP, et al. (2007). Efficacy and Safety of Transcranial Magnetic Stimulation in the Acute Treatment of Major Depression: A Multisite Randomized Controlled Trial. Biol Psychiatry, 62(11):1208-1216. www.ncbi.nlm.nih.gov/pubmed/17573044
  10. George MS, et al. (2010). Daily Left Prefrontal Transcranial Magnetic Stimulation Therapy for Major Depressive Disorder: A Sham-Controlled Randomized Trial. Arch Gen Psychiatry, 67(5):507-516. www.ncbi.nlm.nih.gov/pubmed/20439832
  11. Kessler, RC et al. (2005). Lifetime Prevalence and Age-of-Onset Distributions of DSM-IV Disorders in the National Comorbidity Survey Replication. Arch Gen Psychiatry, 62(6):593-602.
  12. Sackeim HA, et al. (2020). Clinical Outcomes in a Large Registry of Patients with Major Depressive Disorder Treated with Transcranial Magnetic Stimulation. J Affective Disorders, 277(12):65-74.
  13. Gaynes BN, et al. (2008). Cleveland Clinic J of Medicine. 75(1):57-66.
  14. Post A, et al. (2001). J Psychiatric Research, 35:193-215 6.
  15. Liston C, et al.(2014). Biol Psychiatry, 76(7):517-26.
  16. https://factfinder.census.gov/faces/nav/jsf/pages/index.xhtml, accessed 1/16/2018.
  17. Fava M, et al. (2006). A Comparison of Mirtazapine and Nortriptyline Following Two Consecutive Failed Medication Treatments for Depressed Outpatients: A Star*D Report. Am J Psychiatry, 163(7):1161-1172.
  18. McGrath PJ, et al. (2006). Tranylcypromine Versus Venlafaxine Plus Mirtazapine Following Three Failed Antidepressant Medication Trials for Depression: A STAR*D Report. Am J Psychiatry, 163(9):1531-1541.
  19. Carpenter LL, et al. (2012). Transcranial Magnetic Stimulation (TMS) for Major Depression: A Multisite Naturalistic, Observational Study of Acute Treatment Outcomes in Clinical Practice. Depress Anxiety, 29(7):587-596.
  20. Carmi et al, 2018, Am J Psychiatry: Efficacy and Safety of Deep Transcranial Magnetic Stimulation for Obsessive-Compulsive Disorder
  21. Fava M, et al. (2004) Clinical correlates and symptom patterns of anxious depression among patients with major depressive disorder in STAR*D. Psychol Med. 34:1299–1308
  22. Tuinstra D, et al. (2022). Treatment of anxiety symptoms in patients receiving rTMS for treatment resistant depression. Psychiatry Research Communications, 2(1):2772-5987
  23. Substance Abuse and Mental Health Services Administration. (2021). Key substance use and mental health indicators in the United States: Results from the 2020 National Survey on Drug Use and Health (HHS Publication No. PEP21-07-01-003, NSDUH Series H-56). Rockville, MD: Center for Behavioral Health Statistics and Quality, Substance Abuse and Mental Health Services Administration. Retrieved from https://www.samhsa.gov/data/
  24. Harvard Medical School, 2007. National Comorbidity Survey (NCSSC). (2017, August 21). Retrieved from https://www.hcp.med.harvard.edu/ncs/index.php. Data Table 2: 12-month prevalence DSM-IV/WMH-CIDI disorders by sex and cohort.
  25. Brennan, B. P., Lee, C., Elias, J. A., Crosby, J. M., Mathes, B. M., Andre, M. C., et al. (2014). Intensive residential treatment for severe obsessive-compulsive disorder: Characterizing treatment course and predictors of response. Journal of Psychiatric Research, 56(1), 98–105.